Multiple myeloma

Mark P. Purdue, Jonathan N. Hofmann, Elizabeth E. Brown, Celine M. Vachon

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations


Multiple myeloma (MM) is the most common malignancy arising from plasma cells, fully differentiated B lymphocytes that produce the immunoglobulin (Ig) heavy- and light-chain molecules comprising antibodies. MM is characterized by an overproduction of clonal plasma cells in the bone marrow and, in most cases, monoclonal secretion of IgG, IgA, or light-chain Ig. Symptoms of end organ damage (hypercalcemia [C], renal failure [R], anemia [A], or bone lesions [B]), herein referred to as CRAB features, were traditionally a necessary criterion for diagnosing MM; however, improvements in treatment and diagnostic techniques have led to updated diagnostic criteria, enabling intervention among patients before the onset of organ damage. Multiple myeloma is an important cause of lymphoid malignancy (LM) mortality in Western populations. In the United States in 2015, MM was estimated to account for approximately one in every five newly diagnosed LMs, and one in every three LM-related deaths.

Original languageEnglish (US)
Title of host publicationSchottenfeld and Fraumeni Cancer Epidemiology and Prevention, Fourth Edition
PublisherOxford University Press
Number of pages18
ISBN (Electronic)9780190238667
StatePublished - Jan 1 2017


  • Bone marrow
  • Hypercalcemia
  • Lymphocyte
  • Multiple myeloma
  • Plasma cell

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Multiple myeloma'. Together they form a unique fingerprint.

Cite this